Filariasis Treatment Market

Filariasis Treatment Market Snapshot (2023 to 2033)

The global filariasis treatment market is expected to reach US$ 10.96 Billion in 2023 and is projected to exhibit a CAGR of 10.1% from 2023 to 2033. As a disease of the poor and a sign of underdevelopment, filariasis is more prevalent in Africa and the developing world.

Because cities are growing unplanned and mosquito breeding sites are numerous, the prevalence of infection continues to increase. In spite of its serious economic and social consequences, lymphatic filariasis is one of the most prevalent tropical diseases worldwide. Only 0.6% of Indian cases are caused by Brugia malayi, while 99.4% are caused by Wuchereria bancrofti.

An MDA drive for eliminating filaria was conducted previously in 22 districts in Bihar. Local government health workers and Asha workers distributed the drug to every house in backward villages & small towns. 'National Filaria Prevention Programme' was launched by the Central government on March 23, 2020. Anti-filarial drugs are administered annually in a single dose (Mass Drug Administration - MDA) to prevent new infections and diseases.

2018 to 2022 Filariasis Treatment Market Demand Analysis vs. Forecast 2023 to 2033

The global demand for filariasis treatment is projected to increase at a CAGR of 10.1% during the forecast period between 2023 to 2033, reaching a total of US$ 28.68 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 9.6%.

A parasitic infection called lymphatic filariasis continues to threaten 863 million people in 47 countries in the world and requires preventative chemotherapy to prevent the disease from spreading. A preventive chemotherapy combination of safe medicine combinations effectively eliminated lymphatic filariasis by stopping the spread of infection. In the past decade, the spread of infection has been stopped by more than 8.6 billion treatments cumulatively.

Increasing funding and technological advances are likely to drive the future growth of filariasis treatment. The development of new drugs and vaccines, along with the development of new diagnostic tools, are expected to be key drivers for the development of the filariasis treatment market in the future. As filariasis continues to spread in developing countries, the demand for effective treatments is likely to increase, encouraging governments, private companies, and charitable organizations to invest in research and development.

Which are Some Prominent Drivers of the Filariasis Treatment Market?

Growing Incidence of Filariasis Cases to Drive Market Growth

Growing awareness of filariasis' dangers is fueling the market for filariasis treatments. The disease of filariasis has been neglected in the past, yet it can have serious health consequences, including permanent disabilities. In addition, climate change and increased international travel are contributing to the spread of the disease. Therefore, filariasis treatment has become increasingly popular as people become aware of the need for treatment.

Doxycycline, ivermectin, albendazole, and diethylcarbamazine (DEC) are among the drugs that have been used to treat filariasis recently. A number of newer technologies are being used for diagnosing and treating the disease, including PCR-based tests, ELISA tests, and rapid diagnostic tests. Several advances have been made in recent years in using nanoparticles and biodegradable polymers as vectors for delivering drugs. In addition to improving the pharmacokinetics and pharmacodynamic properties of filarial drugs, these technologies could improve the delivery of the drug. As well as the drug-based approach, a combination of vector-based and drug-based approaches remains as a means of enhancing the efficacy of filarial treatment as well.

Governmental Programme to Expand the Market for Filariasis Treatments

Many governmental programs and funds have been initiated that have been designed to treat diseases in various regions across the globe. The government has been launching a series of programs in order to raise awareness and expand the market for treatments in order to stimulate the growth of the market.

For instance, a resolution WHA50.29 from the World Health Assembly urges member states to eliminate lymphatic filariasis. In 2000, the World Health Organization developed the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in response to this problem. Approximately 925 million people received at least one treatment in at least 68 countries between 2000 and 2020, considerably reducing transmission.

Infection prevalence has been reduced below elimination thresholds in 49% (692 million) of those requiring MDA. According to conservative estimates, the program contributed US$ 24 billion to the economy between 2000 and 2007. According to estimates, the treatments provided until 2015 prevented at least US$ 100.5 billion worth of economic losses expected over the life of the cohorts that received these treatments. Another program Accelerated Plan for Eliminating Lymphatic Filariasis 2018 has been launched by the Ministry of Health and Family Welfare. In Arwal (Bihar), Varanasi (Uttar Pradesh), Simdega (Jharkhand), Nagpur (Maharashtra) & Yadgir (Karnataka), the Triple Drug Therapy (IDA) program was successfully implemented. In December 2019, 11 more districts in Uttar Pradesh implemented IDA.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Obstacles Associated with Filariasis Treatment?

Treatment at a High Cost Restricts the Growth of the Market

There are several obstacles hindering the market growth, such as expensive treatment of filariasis, lack of awareness of lymphatic filariasis disease, and insufficient treatment options. The tendency of lymphatic filariasis to manifest late symptoms and the lack of treatments available are likely to be some of the factors that will limit the growth of the market during the forecast period.

Moreover, there is no health remuneration policy on the part of the government, and increased costs and medication side effects are also estimated to inhibit the growth of this market. The treatment for filariasis and other parasitic diseases is not widely available in some parts of the world, making it untreatable. Some strains of filariasis are becoming resistant to certain medications, making treatment more difficult. Increasing resistance to certain drugs makes treating filariasis more difficult. Treatment for filariasis can take a long time, even with medication and other treatments. Additionally, treatment will often involve multiple medications that take several months to reach completion or long-term remission.

Region Wise Insights

How is the Asia Pacific Region's Market for Filariasis Treatment Performing?

Healthcare Spending Improving in Asia Pacific Fuels Filariasis Treatment

The Asia Pacific region is projected to grow at a CAGR of 4% during the forecast period, the fastest of all regions. Increased awareness, increasing spending on healthcare, and a rising incidence of filariasis in the region are the main reasons for the growth in this area. In Asia Pacific, demand for lymphatic filariasis treatment is likely to be fuelled by the presence of major manufacturers, early adoption of new products, and a growing number of patients with lymphatic filariasis.

In the Asian Pacific region, a point-of-care approach has grown significantly, resulting in an emerging health and care market. The treatment market worldwide is set to grow with an increasing number of hospitals in India and China. As a result of new projects and the development of new therapies, it is expected that the market for filariasis treatment will grow significantly in the future. For instance, the LSTM Department of Vector Biology recently signed a contract with the All-India Institute of Medical Sciences, Patna, to conduct future research on disease vectors prevalent in Bihar, such as leishmaniasis, filariasis, malaria, dengue, chikungunya, and Japanese encephalitis.

About 40% of the global burden of filariasis is carried by India and 50% of the worldwide population is at risk of infection due to filariasis. As a result of recent drug developments, there are many new drugs being introduced to the market for the treatment of filariasis. For instance, The Bengal government launched a special drive of mass drug administration to eradicate filariasis in five districts such as Purulia, Bankura, Birbhum, Murshidabad, and West Burdwan. The drive was inaugurated at the cultural community hall of the Bolpur municipality.

What is the Projected Growth Rate for the European Filariasis Treatment Market?

European Reimbursement Policies Favor the Demand for Filariasis Treatment

According to the forecast, the European market will account for about 26% of the worldwide market. The increasing prevalence of the disease in the region is one of the factors contributing to this growth in the region. Medications, surgery, and lifestyle changes are used in Europe to treat filariasis.

There are several medications available that are effective at killing parasites and reducing symptoms, including diethylcarbamazine, albendazole, and ivermectin. Physical deformities caused by the infection are frequently corrected by surgery in the event that they are caused by the infection. The risk of infection can also be reduced by wearing long-sleeved clothing, avoiding mosquito bites, and using insect repellents. Public health measures are also capable of helping to reduce the spread of the infection, such as mosquito control and the improvement of sanitation, to continue to help control the spread of the disease.

Category Wise Insights

How will the Global Drug Market for Filariasis Treatment Grow?

Innovative Drugs to Grow Market for Filariasis Treatment Market

Drugs are projected to grow at a CAGR of 3% from 2023 to 2033. Throughout the next few years, there is expected to be a boost in industry growth due to the introduction of new technologies and increased public awareness about the drugs used in the market. The drug segment accounted for the largest share of the global filariasis treatment market in 2023. As drugs are increasingly used to treat filariasis and major manufacturers launch products that contain diethylcarbamazine, this segment is expected to dominate the global market.

Moxidectin, a topical gel formulation for the treatment of onchocerciasis and loiasis, was recently approved by the US Food and Drug Administration (FDA). In addition to being convenient for patients, the single-dose formulation is expected to increase the market's growth. There are currently no approved treatments for L1 larvae (microfilariae), and all three of these treatments require repeated application over extended periods of time. Ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ABZ) are the only treatments that are approved for use. There are concerns regarding the adverse effects of both single and combinatorial treatment options for onchocerciasis, and IVM-resistant strains are emerging. This creates a significant need for compounds with adult-stage selectivity (macrofilaricidal).

Which Application is Expected to Grow Market for Filariasis Treatment Market?

Hospital to be Most Promising Segment for Filariasis Treatment Market

Based on the application, the global market is segmented into hospitals, clinics, and others. Based on forecasts, hospitals will account for 72% of the filariasis treatment market share.

Among the available treatment options for filariasis, hospitals are the most preferred as they provide the most comprehensive and advanced treatment options for this condition. Hospitals have access to the most sophisticated diagnostic and treatment technologies in order to diagnose and treat patients with filariasis accurately.

As well as providing medication, surgery, and counseling for filariasis patients, hospitals may also provide multiple treatment options for the disease. As an additional benefit, hospitals also provide an environment that is safe and hygienic for patients who are receiving treatment there. Furthermore, hospitals may be able to offer patients support groups and other services in order to help them manage their diseases.

The Start-Up Ecosystem: What is the Future of Growth for Start-up?

Start-ups in the field of filariasis include the following:

• Medicines Development was founded in 2005 in Australia. The firm focuses on the development of therapies for overcoming river blindness (onchocerciasis) and scabies before the disease becomes epidemic. Onchocerciasis, lymphatic filariasis, and scabies are all treated with the company's lead candidate, moxidectin. This substance is a GABA-receptor agonist and a glutamate-gated channel agonist. A phase III clinical trial has been completed for the candidate.
• RTDx was founded in 2017 in, the United States. RTDx designs rapid diagnostic tests and software to diagnose pathogens. In addition to health monitoring, they provide solutions for agriculture monitoring as well. In addition to testing for diseases like Fumonisin, Aflatoxin, Filariasis, Onchocerciasis, and Schistosomiasis, among others, the company also develops rapid lateral flow testing devices. There is also a software product offered by the company that enables the detection of pathogens in agricultural products.
• Biocan Diagnostics offers rapid infectious disease diagnostics in a single step. As part of its product line, it offers immunoassays that are designed to detect tropical viruses such as zika virus, dengue, chikungunya, filariasis, leishmaniasis, malaria, CMV, Chagas, leptospira, gonorrhea, herpes, typhoid, H. pylori, rubella, Strep A & B and influenza.

Competitive Landscape

Research and development activities are underway by key players in the global filariasis treatment market in order to launch novel devices and therapeutics for the treatment of filariasis. In order to gain a competitive edge over their counterparts, companies aim to obtain approval for their new products in a timely manner.

• An LSTM-led partnership has begun its first human trial of a new drug that targets lymphatic filariasis and onchocerciasis. More than 150 million people worldwide suffer from lymphatic filariasis (LF) and onchocerciasis. In contrast to most parasitic worm drugs, AWZ1066S targets Wolbachia, a bacterial symbiont that is crucial to a parasitic worm's survival. Through the direct involvement of Eisai Corp. Ltd., the progress of the drug candidate through the pipeline has been accelerated. This has resulted in the candidate being ready for the first clinical trial in humans.
• The Astellas Global Health Foundation has announced a five-year grant program worth $3.9 million that will provide grants to organizations working to improve the health of the Dominican Republic, Honduras, El Salvador, Guinea Bissau, Senegal, Kenya, and Uganda by improving access to health care, community resilience, and disaster support. Increasing access to health care, building resilient communities, and providing disaster support are just a few of the ways the Foundation's grants will allow it to continue its work in low- and middle-income regions where Astellas has no presence.

Report Scope

Key Segments Profiled in the Filariasis Treatment Industry Survey?

By Type:

• Drugs
• Vaccine

By Application:

• Hospitals
• Clinics
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)